Advertisement

Chronic myelogenous leukemia after treatment with 131I for thyroid carcinoma

Report of a case and review of the literature
  • Daan Walgraeve
    Affiliations
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium.
    Search for articles by this author
  • Gregor Verhoef
    Correspondence
    Address reprint requests to: Dr. Verhoef, Department of Hematology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
    Affiliations
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium.
    Search for articles by this author
  • Michel Stul
    Affiliations
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium.
    Search for articles by this author
  • Jean Jacques Cassiman
    Affiliations
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium.
    Search for articles by this author
  • Cristina Mecucci
    Affiliations
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium.
    Search for articles by this author
  • Herman Van Den Berghe
    Affiliations
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium.
    Search for articles by this author
  • Marc Boogaerts
    Affiliations
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      A patient who developed Philadelphia chromosome-positive chronic myelogenous leukemia (CML) 5 years after successful treatment for thyroid carcinoma, is reported. The Philadelphia chromosome was the typical 9;22 translocation. Southern blot analysis showed breakpoint cluster region rearrangement as observed in classical CML. Up to now, only two cases of CML have been reported following treatment for thyroid carcinoma. This rare complication has also been described after therapy for other malignancies. At present, it is not clear whether the development of CML after thyroid carcinoma represents a therapy-induced complication, a coincidence, or an increased susceptibility to secondary malignancies due to the malignant process itself.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Einhorn N
        Acute leukemia after chemotherapy (Melphalan).
        Cancer. 1978; 41: 444-447
        • Pedersen-Bjergaard J
        • Nisser NI
        • Sorensen HM
        • Hou-Jensen K
        • Larsen MS
        • Ernst P
        • Ersboll J
        • Knudtzon S
        • Rose C
        Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long term treatment with Treosulphan.
        Cancer. 1980; 45: 19-29
        • Einhorn N
        • Eklund G
        • Franzen S
        • Lambert B
        • Lindster F
        • Soderhall S
        Late side effects of chemotherapy in ovarian carcinoma: a cytogenetic, hematologic and statistical study.
        Cancer. 1982; 49: 2234-2241
        • Boivin JF
        • O'Brien K
        Solid cancer after treatment for Hodgkin's disease.
        Cancer. 1988; 66: 2541-2546
        • Edmonds CJ
        • Smith T
        The long term hazards of the treatment of thyroid cancer with radioiodine.
        Br J Radiol. 1986; 59: 45-51
        • Holm LE
        • Wiklund KE
        • Lundell GE
        • Bergman NA
        Cancer risk in population examined with diagnostic doses of 131I.
        J Natl Canc Inst. 1989; 81: 302-306
        • Saenger EL
        • Thoma GE
        • Tompkins EA
        Incidence of leukemia following treatment of hyperthyroidism.
        JAMA. 1986; 205: 855-862
        • Feinberg A
        • Vogelstein B
        Addendum to: a technique for radiolabeling DNA restriction endonuclease fragments to high activity.
        Anal Biochem. 1984; 137: 266-267
        • Mills KI
        • MacKenzy ED
        • Birnie GD
        The site of breakpoint within the bcr is a prognostic factor in Philadelphia positive CML patients.
        Blood. 1988; 72: 1237-1241
        • Swaim WR
        • Windschitl HE
        • Doscherhalmen A
        • Bankole RO
        • Bates HA
        Chronic myelogenous leukemia in Hodgkin's disease: immunofluorescence of cells.
        Cancer. 1971; 27: 569-573
        • Verhoef GEG
        • Demuynck H
        • Stul MS
        • Cassiman JJ
        • Mecucci C
        • Van Den Berghe H
        • Boogaerts MA
        Philadelphia chromosome partial positive chronic myelogenous leukemia in treated Hodgkin's disease.
        Cancer Genet Cytogenet. 1990; 49: 171-176
        • Michalski KA
        • Miles JH
        • Perry MC
        Unusual Ph translocation in a preleukemia.
        Cancer Genet Cytogenet. 1982; 6: 89-90
        • Tester WJ
        • Kinsella TJ
        • Waller B
        • Makuch RW
        • Kelley PA
        • Glatstein E
        • DeVita VT
        Second malignant neoplasms complicating Hodgkin's disease: The national cancer institute experience.
        J Clin Oncol. 1984; 7: 762-769
        • Johnson FB
        • Jacobs EM
        • Wood DA
        Hodgkin's disease: chromosomal abnormalities.
        Calif Med. 1966; 104: 479-482
        • Ezdinli E
        • Sokol JE
        • Aungst GW
        • Kior V
        • Sandberg AA
        Myeloid leukemia in Hodgkin's disease: chromosomal abnormalities.
        Ann Intern Med. 1969; 71: 1097-1100
        • Kaldor JM
        • Day NE
        • Clarke EA
        • Van Leeuwen FE
        • Henry-Amar M
        • Fiorentino MV
        • Bell J
        • Pedersen D
        • Band P
        • Assouline D
        • Koch M
        • Choi W
        • Prior P
        • Blair V
        • Langmark F
        • Kirn V
        • Neal F
        • Peters D
        • Pfeiffer R
        • Karlalainen S
        • Cuzick J
        • Sutcliffe SB
        • Somers R
        • Pellae-Cosset B
        • Papagallo GL
        • Fraser P
        • Storm H
        • Stovall M
        Leukemia following Hodgkin's disease.
        N Engl J Med. 1990; 322: 7-13
        • Dastague N
        • Demur C
        • Pris F
        • Bugat R
        • Attal M
        • Bourouillou G
        • Colombier P
        Association of the Philadelphia chromosome and 5q− in secondary blood disorders.
        Cancer Genet Cytogenet. 1988; 30: 253-259
        • Teichmann JU
        • Sieber G
        • Ludwig WD
        • Karow J
        • Ruehl H
        Chronic myelocytic leukemia as a second neoplasia in the course of chronic lymphocytic leukemia.
        Leuk Res. 1986; 10: 361-368
        • Carcassone Y
        • Gascard E
        Leucémie myéloide succédant à une leucémie lymphoide.
        Med Trop (Mars.). 1968; 105: 339-442
        • Whang-Peng J
        • Gralnick HR
        • Johnson RE
        • Lee EC
        • Lear A
        Chronic granulocytic leukemia (CGL) during the course of chronic lymphocytic leukemia (CLL). Correlation of blood, marrow and spleen morphology and cytogenetics.
        Blood. 1974; 43: 333-339
        • Vilpo JA
        • Klemi P
        • Lassila O
        • de la Chapelle A
        Concomitant presentation of two chronic leukemias: evidence for independent clonal evolution.
        Am J Hematol. 1980; 8: 205-211
        • Khojasteh A
        • Perry MC
        • Taylor HM
        Chronic myelocytic leukemia developing as a second cancer in a patient with chronic lymphocytic leukemia.
        CA-A Cancer J Clinicians. 1981; 31: 172-176
        • Schreiber ZA
        • Axelrod MR
        • Abebe AL
        Coexistence of chronic myelogenous leukemia and chronic lymphocytic leukemia.
        Cancer. 1984; 54: 697-701
        • Philip P
        • Pedersen-Bjergaard J
        Cytogenetic, clinical and cytologic characteristics of radiotherapy-related leukemia.
        Cancer Genet Cytogenet. 1988; 31: 227-236
        • Iurlo A
        • Foa P
        • Maiolo AT
        • Polli EE
        Chronic myelogenous leukemia following radiation therapy for testicular seminoma.
        Blut. 1989; 59: 503-504
        • Kaldor JM
        • Day NE
        • Petterson F
        • Clarke EA
        • Pedersen D
        • Mehnert W
        • Bell J
        • Host H
        • Prior P
        • Karjalainen S
        • Neal F
        • Koch M
        • Band P
        • Choi W
        • Kirn V
        • Arslan A
        • Zarén B
        • Belch AR
        • Storm H
        • Kittelmann B
        • Fraser P
        • Stovall M
        Leukemia following chemotherapy for ovarian cancer.
        N Engl J Med. 1990; 322: 1-6
        • Bundi RS
        • Scott JS
        • Halnan KE
        Chronic myeloid leukemia following radioiodine therapy for carcinoma of the thyroid.
        Br J Radiol. 1977; 50: 61-64
        • Whang-Peng J
        • Young RC
        • Lee EC
        • Longo DL
        • Schechter GP
        • De Vita VT
        Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.
        Blood. 1988; 71: 403-414
        • Brincker H
        • Hansen HS
        • Andersen AP
        Induction of leukemia by 131I treatment of thyroid carcinoma.
        Br J Cancer. 1973; 28: 1348-1350
        • Broownlie
        Leukaemia following radioiodine treatment of thyrotoxicosis.
        N Z Med J. 1968; 67: 621-622
        • Heyssel R
        • Brill AB
        • Woodberry LA
        Leukemia in Hiroshima atomic bomb survivors.
        Blood. 1960; 15: 33-39
        • Darby S
        • Doll R
        Fallout, radiation doses near Dounreay and childhood leukemia.
        Br Med J. 1987; 294: 603-607
        • Forman D
        • Cook-Mozaffari P
        • Darby S
        • Davey G
        • Stratton I
        • Dall R
        • Pike M
        Cancer near nuclear installations.
        Nature. 1987; 329: 499-505
        • Darby SC
        • Kendall GM
        • Fell RP
        • O'Hagan JA
        • Muirhead CR
        • Ennis JR
        • Ball AM
        • Dennis JA
        • Doll R
        A summary of mortality and incidence of cancer in men from the United Kingdom who participated in the U.K.'s atmospheric nuclear weapon tests and experimental programs.
        Br Med J. 1988; 296: 332-338
        • Darby SC
        • Nakashima E
        • Kato H
        A parallel analysis of cancer mortality among atomic bomb survivors and patients with ankylosing spondylitis given X-ray therapy.
        J Natl Cancer Inst. 1985; 75: 1-21